SacraMed
PrivateCompany Overview
SacraMed is a medical technology company that developed a neuromodulation system for the treatment of overactive bladder.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SacraMed Comparables
Compare SacraMed with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neuspera Medical | 93% | |
| Cortex, Inc. | 85% | |
| Amber Therapeutics | 84% |
SacraMed Funding Rounds
Historical fundraising activity
SacraMed Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about SacraMed's valuation, stock price, and market status.
Is SacraMed a public or private company?
SacraMed is a private company.
What is the current stock price of SacraMed?
SacraMed is a private company, so its shares have no public market price. Caplight tracks SacraMed's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SacraMed worth (valuation)?
Valuation information for SacraMed is not publicly available.
Can I buy SacraMed stock?
SacraMed shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SacraMed's last funding round?
Funding round information for SacraMed is not publicly available.
Who are the main investors in SacraMed?
Investor information for SacraMed is not publicly disclosed.
Will SacraMed IPO soon?
No public IPO plans have been announced for SacraMed.
How can I track SacraMed secondary market activity?
Caplight tracks bids, offers, and trades in SacraMed's shares on secondary markets.